Regulatory GSK’s $10.6B Nuvalent bet pays off early as FDA approves lung cancer drug BioSpaceJideytro is GSK's first approved product for lung cancer.OncologyRead full story pharminent July 23, 2026 (Last updated: July 23, 2026) BioSpace Jideytro is GSK’s first approved product for lung cancer. Oncology Read full story Post navigation Previous: Arrowhead’s Plozasiran Cuts Triglycerides Roughly 80% in Two Phase 3 TrialsNext: Lilly plans Q1 2027 filing for obesity triple retatrutide Related Stories Regulatory FDA clears Takeda, Protagonist’s first-in-class PV drug pharminent August 31, 2026 Regulatory FDA green lights Priovant drug for rare skin disease pharminent August 28, 2026 Regulatory Neurocrine receives FDA IND Acceptance for Alzheimer’s Ph2 pharminent August 26, 2026